{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:27:29Z","timestamp":1786580849802,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56251-9","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:04:51Z","timestamp":1780441491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["True reactivation versus transient viremia: a retrospective analysis of HBV reactivation in resolved infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Tadashi","family":"Inuzuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kayahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Seno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"14","key":"56251_CR1","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"JL Dienstag","year":"2008","unstructured":"Dienstag, J. L. Hepatitis B virus infection. N. Engl. J. Med. 359(14), 1486\u20131500 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"56251_CR2","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba, R. & Liang, T. J. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152 (6), 1297\u20131309 (2017).","journal-title":"Gastroenterology"},{"issue":"2","key":"56251_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo, W. & Johnson, P. J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2), 209\u2013220 (2006).","journal-title":"Hepatology"},{"issue":"3","key":"56251_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2014.04.033","volume":"61","author":"T Inuzuka","year":"2014","unstructured":"Inuzuka, T. et al. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. J. Hepatol. 61(3), 492\u2013501 (2014).","journal-title":"J. Hepatol."},{"issue":"2","key":"56251_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hep.510310232","volume":"31","author":"H Marusawa","year":"2000","unstructured":"Marusawa, H. et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31(2), 488\u2013495 (2000).","journal-title":"Hepatology"},{"issue":"4","key":"56251_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo, W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved Hepatitis B undergoing anticancer therapy with or without Rituximab. J. Clin. Oncol. 27(4), 605\u2013611 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"56251_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic Hepatitis B: AASLD 2018 Hepatitis B guidance. Hepatology 67(4), 1560\u20131599 (2018).","journal-title":"Hepatology"},{"issue":"2","key":"56251_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"EASL clinical practice guidelines on the","year":"2025","unstructured":"EASL clinical practice guidelines on the. management of hepatitis B virus infection. J. Hepatol. 83 (2), 502\u2013583 (2025).","journal-title":"J. Hepatol."},{"issue":"2","key":"56251_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali, F. S. et al. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology 168 (2), 267\u2013284 (2025).","journal-title":"Gastroenterology"},{"issue":"5","key":"56251_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau, G. et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 15(5), 1031\u20131048 (2021).","journal-title":"Hepatol Int"},{"issue":"8","key":"56251_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Japan society of hepatology guidelines for the","year":"2020","unstructured":"Japan society of hepatology guidelines for the. management of hepatitis B virus infection: 2019 update. Hepatol. Res. 50 (8), 892\u2013923 (2020).","journal-title":"Hepatol. Res."},{"issue":"1","key":"56251_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui, C. K. et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131(1), 59\u201368 (2006).","journal-title":"Gastroenterology"},{"issue":"3","key":"56251_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1703614","volume":"30","author":"P Seth","year":"2002","unstructured":"Seth, P. et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30(3), 189\u2013194 (2002).","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"56251_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13075-019-2053-1","volume":"21","author":"W Fukuda","year":"2019","unstructured":"Fukuda, W. et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res. Ther. 21 (1), 255 (2019).","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"56251_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 22(5), 1170\u20131180 (2011).","journal-title":"Ann Oncol"},{"issue":"35","key":"56251_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.1278","volume":"31","author":"S Kusumoto","year":"2013","unstructured":"Kusumoto, S. et al. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?. J Clin Oncol 31(35), 4480 (2013).","journal-title":"J Clin Oncol"},{"issue":"4","key":"56251_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/phar.2508","volume":"41","author":"CJ Tan","year":"2021","unstructured":"Tan, C. J. et al. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy 41 (4), 332\u2013341 (2021).","journal-title":"Pharmacotherapy"},{"issue":"2","key":"56251_CR18","doi-asserted-by":"publisher","first-page":"e28452","DOI":"10.1002\/jmv.28452","volume":"95","author":"G Suda","year":"2023","unstructured":"Suda, G. et al. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J. Med. Virol. 95 (2), e28452 (2023).","journal-title":"J. Med. Virol."},{"issue":"5","key":"56251_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto, S. et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in b-cell lymphoma: A prospective observational study. Clin. Infect. Dis. 61(5), 719\u2013729 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"56251_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00535-016-1168-2","volume":"51","author":"S Mochida","year":"2016","unstructured":"Mochida, S. et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J. Gastroenterol. 51 (10), 999\u20131010 (2016).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"56251_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10665-3","volume":"12","author":"M Fujita","year":"2022","unstructured":"Fujita, M. et al. Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for b-cell non-Hodgkin lymphoma. Sci. Rep. 12(1), 7365 (2022).","journal-title":"Sci. Rep."},{"key":"56251_CR22","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.eclinm.2024.103038","volume":"80","author":"KW Cheung","year":"2025","unstructured":"Cheung, K. W. et al. Accelerating the momentum to achieve global elimination of hepatitis B infection: a scoping review of hepatitis B guidelines to reduce mother to child transmission. EClinicalMedicine 80, 103038 (2025).","journal-title":"EClinicalMedicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56251-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56251-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56251-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:35:00Z","timestamp":1786577700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56251-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56251"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56251-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Kyoto University (Approval No. R4430-1). Ethical approval for this multi-center retrospective study, including data collection at Kurashiki Central Hospital, was covered under this single institutional review board approval.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients included in the study through the opt-out method.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25208"}}